ClinicalTrials.gg
CompletedNCT02117713IMAGINE-IIUpdated Jul 1, 2021Results posted

An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome

A Phase 2 interventional study of LUM001 (Maralixibat) in Alagille Syndrome, sponsored by Mirum Pharmaceuticals, Inc.. Completed at 11 sites in 2 countries. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2021-07-01.

Sponsored by Mirum Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
1 Year to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc. — 2 open to participants now, 2 under way, none of them phase 3. Alagille Syndrome · Mirum Pharmaceuticals, Inc..

Started
2015
the only one that year
Phase 2
6 of 10
none open now
Registered
4th of 10
by date

Among the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc., this one is the only one that started in 2015, is one of 6 in phase 2, and was the 4th registered.

Alagille Syndrome

31 studies on the registry are indexed under Alagille Syndrome; 11 are open to participants now.

Browse Alagille Syndrome studies →

Open to participants now

2 of the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc. are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 10 Alagille Syndrome studies recruiting now, 7 (70%) set no upper age limit and 3 (30%) stop at 75 or younger; 9 take children under 18; none take healthy volunteers.

This study: 1 Year to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc., or all of them as a file.
02

Study summary

This is a multicentre, extension study of LUM001 in children diagnosed with Alagille Syndrome who have completed participation in a core LUM001 treatment protocol. The primary objective is to evaluate long-term safety and tolerability of LUM001. Efficacy will be assessed by evaluating the effect of LUM001 on the biochemical markers and pruritus associated with Alagille Syndrome.

03

Conditions studied

  • Alagille Syndrome

Browse trials for

04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, 12 months to 18 years of age.
  2. Competent to provide and assent (per institutional review board/Ethics Committee [IRB/EC]), as appropriate.
  3. Completed participation in the LUM001-301 protocol.
  4. Females of must have a negative urine pregnancy test [beta human chorionic gonadotropin (beta-hCG)] at the Baseline Visit.
  5. Sexually active females must be prepared to use an effective method of during the trial.

    Effective methods of contraception are considered to be:

    1. Hormonal (for example, contraceptive pill, patch, intramuscular implant or injection); or
    2. Barrier method, for example, (a) condom with spermicide, or (b) diaphragm, with spermicide; or
    3. Intrauterine device (IUD).
  6. Participants above the age of assent and caregivers and children must be able to read and understand English or Spanish.
  7. Caregivers (and age appropriate participants) must have access to phone for scheduled calls from study site.
  8. Caregivers (and age appropriate participants) must be willing and able to complete a daily electronic diary (ItchRO) during the first consecutive 12 weeks of the study and then for 4 consecutive weeks following the Week 24 and Week 44 visits.
  9. Caregivers (and age appropriate participants) must digitally accept the licensing agreement in the ItchRO electronic diary software at the outset of the study.
  10. Eligible participants must be able to adhere to local Ethics Committee or Institutional Review Board (IRB) blood volume limits for laboratory testing.
  11. The participant has completed the protocol either through Week 144, or the End of Trial visit, or has received permission from the sponsor and the Premier Medical monitor to re-enter the study in the long-term, optional follow-up treatment period 2.
  12. Females of child-bearing potential must have a negative urine or serum pregnancy test (beta-HCG]) at the time of entry into the long-term optional follow-up treatment period 2.
  13. Male and female participants of child-bearing potential who are sexually active, or are not currently sexually active, but become sexually active during the study or for 30 days following the last dose of study drug, must agree to use acceptable contraception during the study.
  14. Informed consent and assent (per IRB/EC) as appropriate.
  15. Caregivers (and age appropriate participants) must have access to phone for scheduled calls from study site.
  16. Caregivers (and age appropriate participants) must be willing to follow the rules of eDiary completion.

Exclusion criteria

Exclusion Criteria:

  1. Experienced an adverse event or serious adverse event (SAE) related to the study drug during the LUM001-301 protocol that led to the discontinuation of the participant from the core study.
  2. Any conditions or abnormalities (including laboratory abnormalities) which in the opinion of the Investigator, Medical Monitor or ChiLDReN Protocol Chair, may compromise the safety of the participant, or interfere with the participant participating in or completing the study.
  3. History or known presence of gallstones or kidney stones.
  4. History of non-adherence during the participant's participation in the LUM001-301 protocol. Non-adherence is defined by dosing compliance (dosing compliance is calculated by [the total number of doses that were actually taken by the participant] divided by [the total number of doses that should have been taken by the participant] multiplied by 100) of less than 80% in the LUM001-301 protocol.
  5. Unlikely to comply with the study protocol, or unsuitable for any other reason, as judged by the investigator.
  6. All above exclusion criteria will apply upon re-entry into the long-term, optional follow-up treatment period 2.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    LUM001 (Maralixibat)

    Participant will receive LUM001 also known as Maralixibat (MRX) administered orally once per day.

    Drug: LUM001 (Maralixibat)

Interventions

  • Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 280 micrograms per kilogram (mcg/kg).

06

What researchers measure

Primary outcomes

  1. Change From MRX Baseline to Week 48 in Fasting Serum Bile Acid (sBA)

    This primacy efficacy endpoint is the mean change from MRX baseline to week 48 in fasting sBA levels.

    Time frame: Baseline to Week 48

Secondary outcomes

  1. Change From MRX Baseline to Week 216 in Fasting Serum Bile Acid (sBA)

    The secondary endpoint of this study was the mean change from MRX baseline to week 216 fasting in sBA levels.

    Time frame: Baseline to week 216

  2. Change From Baseline to Week 218 in Pruritus

    This secondary efficacy endpoint is the mean change from MRX baseline over time to week 218 in pruritus as measured by ItchRO(Obs) weekly average morning severity score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe). Results reported here are the long-term results.

    Time frame: Baseline to Week 218

  3. Change From Baseline to Week 216 in Alanine Aminotransferase

    This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in ALT levels.

    Time frame: Baseline to week 216

  4. Change From Baseline to End of Treatment in Alkaline Phosphatase

    This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in ALP levels.

    Time frame: Baseline to Week 216

  5. Change From MRX Baseline to Week 216 in Aspartate Aminotransferase

    This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in AST levels.

    Time frame: Baseline to week 216

  6. Change From MRX Baseline to Week 216 in Clinician Xanthoma Severity Score

    This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in clinician xanthoma severity scores. It is based on a 0-4 scale to rate the number of lesions present and the degree to which the lesions interfere or limit activities. Clinician xanthoma severity scores range from 0 to 4, with a score of zero representing no evidence of xanthomatosis and a score of 4 representing xanthoma so severe that it is disabling.

    Time frame: Baseline to week 216

  7. Change From Baseline to Week 216/LOFC Clinician Scratch Scale (CSS) Score

    This secondary efficacy endpoint is the mean change from MRX baseline over time to week 216/LOCF in pruritus as measured by the Clinician Scratch Scale (CSS). The Clinician Scratch Scale uses a 5-point scale, where 0 = none; 1 = rubbing or mild scratching when undistracted; 2 = active scratching without evident skin abrasions; 3 = abrasion evident; 4 = cutaneous mutilation, haemorrhage and scarring evident.

    Time frame: Baseline to Week 216

  8. Change From MRX Baseline to Week 216 in Gamma Glutamyltransferase

    This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in GGT.

    Time frame: Baseline to Week 216

  9. Mean Change From MRX Baseline to Week 216 in Total Bilirubin

    This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in total bilirubin.

    Time frame: Baseline to week 216

  10. Mean Change From MRX Baseline to Week 216 in Direct Bilirubin

    This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in direct bilirubin.

    Time frame: Baseline to week 216

07

Results

Posted Jun 22, 2021
Limitations and caveats
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Participant flow

Week 48
Participant flow — Week 48
MilestoneLUM001 (Maralixibat)
Started34
Completed26
Not completed8
Withdrew: Adverse event4
Withdrew: Withdrawal by caregiver2
Withdrew: Did not consent to protocol amendment 42
Long Term Follow-up Treatment
Participant flow — Long Term Follow-up Treatment
MilestoneLUM001 (Maralixibat)
Started26
Completed20
Not completed6
Withdrew: Adverse event3
Withdrew: Progressive disease2
Withdrew: Non-compliance with study drug1

Outcome measures

PrimaryChange From MRX Baseline to Week 48 in Fasting Serum Bile Acid (sBA)

This primacy efficacy endpoint is the mean change from MRX baseline to week 48 in fasting sBA levels.

Time frame:
Baseline to Week 48
Reported as:
Mean · μmol/L
Change From MRX Baseline to Week 48 in Fasting Serum Bile Acid (sBA)
μmol/LMRX Baseline ValueMaralixibat Week 48 Values
Change From MRX Baseline to Week 48 in Fasting Serum Bile Acid (sBA)223.62 ± 205.041157.35 ± 178.538
Statistical analysis
  • MRX Baseline Value vs Maralixibat Week 48 Values · Student's t-test · p = 0.1157 · Mean difference (net): -28.59 · 95% CI -64.72 to 7.54Difference is only calculated in participants who had baseline and week 48 values for n= 26
SecondaryChange From MRX Baseline to Week 216 in Fasting Serum Bile Acid (sBA)

The secondary endpoint of this study was the mean change from MRX baseline to week 216 fasting in sBA levels.

Time frame:
Baseline to week 216
Reported as:
Mean · μmol/L
Change From MRX Baseline to Week 216 in Fasting Serum Bile Acid (sBA)
μmol/LMaralixibat Baseline ValuesWeek 216
Change From MRX Baseline to Week 216 in Fasting Serum Bile Acid (sBA)223.62 ± 205.041118.81 ± 126.878
Statistical analysis
  • Maralixibat Baseline Values vs Week 216 · Student's t-test · p = 0.1469 · Mean difference (net): -45.15 · 95% CI -109.48 to 19.19
SecondaryChange From Baseline to Week 218 in Pruritus

This secondary efficacy endpoint is the mean change from MRX baseline over time to week 218 in pruritus as measured by ItchRO(Obs) weekly average morning severity score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe). Results reported here are the long-term results.

Time frame:
Baseline to Week 218
Reported as:
Mean · score on a scale
Change From Baseline to Week 218 in Pruritus
score on a scaleMaralixibat Baseline ValuesWeek 218
Change From Baseline to Week 218 in Pruritus2.533 ± 0.84230.429 ± 0.8571
Statistical analysis
  • Maralixibat Baseline Values vs Week 218 · Student's t-test · p = 0.005 · Mean difference (net): -2.353 · 95% CI -3.101 to -1.606Difference is only calculated in participants who had baseline and week 218 values for n=6
SecondaryChange From Baseline to Week 216 in Alanine Aminotransferase

This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in ALT levels.

Time frame:
Baseline to week 216
Reported as:
Mean · U/L
Change From Baseline to Week 216 in Alanine Aminotransferase
U/LMRX Baseline ValueWeek 216 Values
Change From Baseline to Week 216 in Alanine Aminotransferase152.9 ± 82.26222.4 ± 126.53
Statistical analysis
  • MRX Baseline Value vs Week 216 Values · Student's t-test · p = 0.2607 · Mean difference (net): 56.0 · 95% CI -54.4 to 166.4Difference is only calculated in participants who had baseline and week 216 values for n=7
SecondaryChange From Baseline to End of Treatment in Alkaline Phosphatase

This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in ALP levels.

Time frame:
Baseline to Week 216
Reported as:
Mean · U/L
Change From Baseline to End of Treatment in Alkaline Phosphatase
U/LMRX Baseline ValueWeek 216 Values
Change From Baseline to End of Treatment in Alkaline Phosphatase598.8 ± 199.89528.3 ± 221.93
Statistical analysis
  • MRX Baseline Value vs Week 216 Values · Student's t-test · p = 0.1340 · Mean difference (net): -141.6 · 95% CI -341.6 to 58.4Difference is only calculated in participants who had baseline and week 216 values for n=7
SecondaryChange From MRX Baseline to Week 216 in Aspartate Aminotransferase

This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in AST levels.

Time frame:
Baseline to week 216
Reported as:
Mean · U/L
Change From MRX Baseline to Week 216 in Aspartate Aminotransferase
U/LMRX Baseline ValueWeek 216
Change From MRX Baseline to Week 216 in Aspartate Aminotransferase149.7 ± 88.27231.4 ± 122.26
Statistical analysis
  • MRX Baseline Value vs Week 216 · Student's t-test · p = 0.1474 · Mean difference (net): 47.6 · 95% CI -22.4 to 117.6Difference is only calculated in participants who had baseline and week 216 values for n=7
SecondaryChange From MRX Baseline to Week 216 in Clinician Xanthoma Severity Score

This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in clinician xanthoma severity scores. It is based on a 0-4 scale to rate the number of lesions present and the degree to which the lesions interfere or limit activities. Clinician xanthoma severity scores range from 0 to 4, with a score of zero representing no evidence of xanthomatosis and a score of 4 representing xanthoma so severe that it is disabling.

Time frame:
Baseline to week 216
Reported as:
Mean · Points
Change From MRX Baseline to Week 216 in Clinician Xanthoma Severity Score
PointsMRX Baseline ValueWeek 216
Change From MRX Baseline to Week 216 in Clinician Xanthoma Severity Score0.9 ± 1.331.1 ± 1.68
Statistical analysis
  • MRX Baseline Value vs Week 216 · Student's t-test · p = 1.00 · Mean difference (net): 0 · 95% CI -0.5 to 0.5Difference is only calculated in participants who had baseline and week 216 values for n=7
SecondaryChange From Baseline to Week 216/LOFC Clinician Scratch Scale (CSS) Score

This secondary efficacy endpoint is the mean change from MRX baseline over time to week 216/LOCF in pruritus as measured by the Clinician Scratch Scale (CSS). The Clinician Scratch Scale uses a 5-point scale, where 0 = none; 1 = rubbing or mild scratching when undistracted; 2 = active scratching without evident skin abrasions; 3 = abrasion evident; 4 = cutaneous mutilation, haemorrhage and scarring evident.

Time frame:
Baseline to Week 216
Reported as:
Mean · Points
Change From Baseline to Week 216/LOFC Clinician Scratch Scale (CSS) Score
PointsMRX Baseline ValueWeek 216
Change From Baseline to Week 216/LOFC Clinician Scratch Scale (CSS) Score2.9 ± 1.081.1 ± 1.07
Statistical analysis
  • MRX Baseline Value vs Week 216 · Student's t-test · p = 0.0167 · Mean difference (net): -1.7 · 95% CI -3 to -0.4Difference is only calculated in participants who had baseline and week 216 values for n=7
SecondaryChange From MRX Baseline to Week 216 in Gamma Glutamyltransferase

This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in GGT.

Time frame:
Baseline to Week 216
Reported as:
Mean · U/L
Change From MRX Baseline to Week 216 in Gamma Glutamyltransferase
U/LMRX Baseline ValueWeek 216 Values
Change From MRX Baseline to Week 216 in Gamma Glutamyltransferase493.5 ± 380.29431 ± 235.35
Statistical analysis
  • MRX Baseline Value vs Week 216 Values · Student's t-test · p = 0.9108 · Mean difference (net): 10.9 · 95% CI -216.6 to 238.3Difference is only calculated in participants who had baseline and week 216 values for n=7
SecondaryMean Change From MRX Baseline to Week 216 in Total Bilirubin

This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in total bilirubin.

Time frame:
Baseline to week 216
Reported as:
Mean · mg/dL
Mean Change From MRX Baseline to Week 216 in Total Bilirubin
mg/dLMRX Baseline ValueWeek 216
Mean Change From MRX Baseline to Week 216 in Total Bilirubin5.62 ± 6.4205.39 ± 5.181
Statistical analysis
  • MRX Baseline Value vs Week 216 · Student's t-test · p = 0.1207 · Mean difference (net): 0.1207 · 95% CI -3.03 to 0.45Difference is only calculated in participants who had baseline and week 216 values for n=7
SecondaryMean Change From MRX Baseline to Week 216 in Direct Bilirubin

This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in direct bilirubin.

Time frame:
Baseline to week 216
Reported as:
Mean · mg/dL
Mean Change From MRX Baseline to Week 216 in Direct Bilirubin
mg/dLMRX Baseline ValueWeek 216 Values
Mean Change From MRX Baseline to Week 216 in Direct Bilirubin3.541 ± 3.64333.714 ± 3.8369
Statistical analysis
  • MRX Baseline Value vs Week 216 Values · Student's t-test · p = 0.0927 · Mean difference (net): -0.943 · 95% CI -2.098 to 0.212Difference is only calculated in participants who had baseline and week 216 values for n=7

Adverse events

Collected over Baseline to End of Treatment (Week 216). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LUM001 (Maralixibat)0/34 (0%)6/34 (17.6%)34/34 (100%)
Most frequent serious events
Most frequent serious events
EventLUM001 (Maralixibat)
AnaemiaBlood and lymphatic system disorders1/34
HaematemesisGastrointestinal disorders1/34
HaematocheziaGastrointestinal disorders1/34
Autoimmune hepatitisHepatobiliary disorders1/34
Chronic hepatic failureHepatobiliary disorders1/34
Fungal infectionInfections and infestations1/34
MalnutritionMetabolism and nutrition disorders1/34
EpistaxisRespiratory, thoracic and mediastinal disorders1/34
Most frequent other events
Showing 10 of 176
Most frequent other events
EventLUM001 (Maralixibat)
Upper respiratory tract infectionInfections and infestations16/34
PyrexiaGeneral disorders15/34
DiarrhoeaGastrointestinal disorders13/34
CoughRespiratory, thoracic and mediastinal disorders13/34
HeadacheNervous system disorders12/34
VomitingGastrointestinal disorders10/34
NasopharyngitisInfections and infestations10/34
Alanine aminotransferase increasedInvestigations10/34
Oropharyngeal painRespiratory, thoracic and mediastinal disorders9/34
Aspartate aminotransferase increasedInvestigations8/34

Baseline characteristics

In the lead-in Study LUM001-301, participants were randomized to receive either placebo or active drug (MRX). The last observation obtained before first dose of MRX (either for participants who received MRX or placebo LUM001-301) was used as the MRX baseline observation for all calculations of change. For participants who were assigned MRX in LUM001-301, results at each post-baseline analysis visit included up to 13 more weeks of treatment than participants who were assigned placebo.

Age, Continuous
Age, Continuous(years of age)Core Study Period
Mean7 ± 4.55
Sex: Female, Male
Sex: Female, Male(Participants)Core Study Period
Female14
Male20
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Core Study Period
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American4
White27
More than one race1
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)Core Study Period
Canada4
United States30
08

Study locations

11 sites
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • University of California at San Francisco Children's Hospital
    San Francisco, California 94143, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Riley Hospital for Children
    Indianapolis, Indiana 46202, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19147, United States
  • Children's Hospital of Pittsburgh of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • Baylor College of Medicine/Texas Children's Hospital
    Houston, Texas 77030, United States
  • University of Utah
    Salt Lake City, Utah 84113, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2015 to primary completion in Jun 2020, 62 months.

Results were first posted in Jun 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2014
First posted
Apr 21, 2014
StartActual
Mar 16, 2015
Primary completionActual
Jun 1, 2020
CompletionActual
Jun 1, 2020
Results first posted
Jun 22, 2021
Last update
Jul 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02117713
Collaborators
Lumena Pharmaceuticals, Inc., Childhood Liver Disease Research and Education Network
Responsible party
Sponsor
First posted
Apr 21, 2014
Start date
Mar 16, 2015
Primary completion
Jun 1, 2020
Completion
Jun 1, 2020
Results posted
Jun 22, 2021
Last update
Jul 1, 2021

Study contacts

Study Director
study director · Mirum

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maralixibat

Start the discussion